Working… Menu

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017))

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04223778
Recruitment Status : Active, not recruiting
First Posted : January 10, 2020
Last Update Posted : October 11, 2021
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : September 8, 2021
Estimated Study Completion Date : September 16, 2022